stockrowPerrigo Company plc
PRGO Healthcare Drug Manufacturers Specialty & Generic
Perrigo Company plc’s revenue for fiscal 2025 (year ended December 2025) was $4.3 billion, down 2.75% from fiscal 2024.
- Revenue
- −5.24%
- EPS
- −494.6%
- Free cash flow
- +138.5%
- Total debt
- −9.62%
Quarter to September 2026, against a year earlier
Follow PRGO
Alert me
Perrigo Company plc (PRGO) Return on equity
Perrigo Company plc's return on equity over the twelve months to 30 September 2026 was −51.4%, down 12.1 percentage points from fiscal 2025 (−39.3%). Over the past ten years it has ranged from −50.0% (fiscal 2016) to 2.55% (fiscal 2019); the current reading is higher than 17% of that period. That is below the Drug Manufacturers Specialty & Generic industry median of −0.80% and below the Healthcare sector median of −26.3%.
Return on equity, annual
Embed this chart
Annual newest first
| Period | Return on equity | Change (points) |
|---|---|---|
| FY2025 | −39.3% | (35.51) |
| FY2024 | −3.78% | (3.52) |
| FY2023 | −0.26% | 2.55 |
| FY2022 | −2.81% | (1.53) |
| FY2021 | −1.28% | 1.56 |
| FY2020 | −2.84% | (5.39) |
| FY2019 | 2.55% | 0.34 |
| FY2018 | 2.21% | 0.24 |
| FY2017 | 1.97% | 51.93 |
| FY2016 | −50.0% | (50.37) |
Against its own ten years
Return on equity against peers
| Company | Return on equity |
|---|---|
| BCRX BioCryst Pharmaceuticals, Inc. compare | 91.6% |
| ANIP ANI Pharmaceuticals, Inc. compare | 20.5% |
| PBH Prestige Consumer Healthcare Inc. compare | 8.23% |
| HCM HUTCHMED (China) Limited Sponsored ADR compare | 0.00% |
| RGC Regencell Bioscience Holdings Limited compare | 0.00% |
| ALVO Alvotech compare | 0.00% |
| XERS Xeris Biopharma Holdings, Inc. compare | −27.1% |
| TRLV Trulieve Cannabis Corp. compare | −45.5% |
| PRGO Perrigo Company plc | −51.4% |
| Drug Manufacturers Specialty & Generic industry median | −0.80% |
| Healthcare sector median | −26.3% |
| Market median | 0.51% |
What Return on equity is
ROE shows how much profit a company earns for its shareholders on the equity they have in the business.
Annual: Net Income Allotted to Shareholders ÷ Average Common Equity; TTM: Net Income Allotted to Shareholders ÷ Average Common Equity (latest quarter)
More on PRGO
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement